NCT06199791View on ClinicalTrials.gov

Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

May 9, 2023

Study Completion Date

June 14, 2023

Conditions
Fasting
Interventions
DRUG

Lamotrigine 100 MG

tablets

Trial Locations (1)

Unknown

Biopharma Services INC, Toronto

Sponsors

Collaborators (1)

BioPharma Services Inc.
All Listed Sponsors
collaborator

BioPharma Services Inc.

INDUSTRY

lead

Desitin Arzneimittel GmbH

INDUSTRY